Novo Nordisk A/S
Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup […]
Read More
European markets poised for lackluster open ahead of shortened trading session
LONDON — European markets are expected to open in flat to negative territory as investors take stock of the volatile year during Christmas Eve’s shortened trading session. The U.K.’s FTSE 100 and Germany’s DAX were last seen edging below the flatline, while France’s CAC was 0.1% lower according to data from IG Group. The pan-European Stoxx […]
Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]
Read More
Stocks making the biggest moves midday: Novo Nordisk, ServiceNow, Freeport-McMoRan, Structure Therapeutics & more
Check out the companies making headlines in midday trading. ServiceNow — Shares of the software company fell nearly 3% after it said it would acquire cybersecurity startup Armis for $7.75 billion . The deal, which should close next year, will bolster ServiceNow’s cybersecurity offerings. Mining stocks — With prices of gold, silver and copper at […]
Read More
Novo Nordisk’s new obesity pill, Alphabet’s data center deal, the end of EV euphoria and more in Morning Squawk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading […]
Read More
Stocks making the biggest moves premarket: Novo Nordisk, Huntington Ingalls Industries, Zim Integrated Shipping Services & more
Check out the companies making headlines before the bell. ZIM Integrated Shipping Services — The shipping services firm jumped 10% after its executives said a board is evaluating multiple competitive acquisition proposals. Novo Nordisk — The drugmaker jumped 7% in the premarket after the company’s GLP-1 pill received approval from the Food and Drug Administration. […]
Read More
Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
Shares in Novo Nordisk surged 6% Monday, after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly. The pill’s starting dose of 1.5 milligrams will be […]
Read More
Nine of the largest pharma companies ink deals with Trump to lower drug prices
President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with […]
Read More
Wall Street banked on a flurry of deals under Trump in 2025. It wasn’t that simple
The Wall Street Bull statue covered in snow on Nov. 15, 2018. Erik Mcgregor | Lightrocket | Getty Images Wall Street expected U.S. mergers and acquisitions to roar back in 2025. The reality was something closer to fits and starts. Following the re-election of President Donald Trump more than a year ago, executives and bankers […]
Read More
This is how exposed European Big Pharma is to the U.S.
Novo Nordisk CEO Maziar Mike Doustdar shakes hands with U.S. President Donald Trump during an event to announce a deal with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White House in Washington, D.C., U.S., November 6, 2025. Jonathan Ernst | […]
Read More